P. Österlund, L. Soveri, H. Isoniemi, T. Poussa, T. Alanko et al., Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy, British Journal of Cancer, vol.104, issue.4, pp.599-604, 2011.
DOI : 10.1200/JCO.2008.16.1612

O. Abdel-rahman and A. Lamarca, Development of sorafenib-related side effects in patients diagnosed with advanced hepatocellular carcinoma treated with sorafenib: a systematic-review and meta-analysis of the impact on survival, Expert Review of Gastroenterology & Hepatology, vol.21, issue.14, pp.75-83, 2017.
DOI : 10.1158/2326-6066.CIR-13-0146

A. Abdelaziz and U. Vaishampayan, Cabozantinib for Renal Cell Carcinoma: Current and Future Paradigms, Current Treatment Options in Oncology, vol.122, issue.4, pp.11864-11881, 2017.
DOI : 10.1200/JCO.2016.70.7398

G. K. Abou-alfa, L. Schwartz, S. Ricci, D. Amadori, A. Santoro et al., Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma, Journal of Clinical Oncology, vol.24, issue.26, pp.4293-4300, 2006.
DOI : 10.1200/JCO.2005.01.3441

C. Abou-fayçal, A. Hatat, S. Gazzeri, and B. Eymin, Splice Variants of the RTK Family: Their Role in Tumour Progression and Response to Targeted Therapy, International Journal of Molecular Sciences, vol.23, issue.2, 2017.
DOI : 10.1038/nm.4097

G. Adrian, V. Marcel, B. Robert, and T. Richard, A Comparison of Physicochemical Property Profiles of Marketed Oral Drugs and Orally Bioavailable Anti-Cancer Protein Kinase Inhibitors in Clinical Development, Current Topics in Medicinal Chemistry, vol.7, issue.14, pp.1408-1422, 2007.
DOI : 10.2174/156802607781696819

S. L. Beedie, C. Mahony, H. M. Walker, C. H. Chau, W. D. Figg et al., Shared mechanism of teratogenicity of anti-angiogenic drugs identified in the chicken embryo model, Scientific Reports, vol.19, issue.1, 2016.
DOI : 10.1038/sj.leu.2403776

A. Bellesoeur, E. Carton, O. Mir, L. Groussin, B. Blanchet et al., Critical role of sorafenib exposure over time for its antitumor activity in thyroid cancer, Investigational New Drugs, vol.55, issue.3, pp.569-572, 2014.
DOI : 10.1007/s00280-004-0876-0

G. Bergers and D. Hanahan, Modes of resistance to anti-angiogenic therapy, Nature Reviews Cancer, vol.25, issue.8, pp.592-603, 2008.
DOI : 10.1016/S0002-9440(10)64083-7

J. Bergh, I. M. Bondarenko, M. R. Lichinitser, A. Liljegren, R. Greil et al., First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study, Journal of Clinical Oncology, vol.30, issue.9, pp.921-929, 2012.
DOI : 10.1200/JCO.2011.35.7376

E. Biziota, L. Mavroeidis, E. Hatzimichael, and P. Pappas, Metronomic chemotherapy: A potent macerator of cancer by inducing angiogenesis suppression and antitumor immune activation, Cancer Letters, vol.400, pp.243-251, 2017.
DOI : 10.1016/j.canlet.2016.12.018

J. Bruix, S. Qin, P. Merle, A. Granito, Y. Huang et al., Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial, Resorce Investigators, pp.56-66, 2017.
DOI : 10.1016/S0140-6736(16)32453-9

P. A. Bunn and W. Franklin, Epidermal growth factor receptor expression, signal pathway, and inhibitors in non[ndash ]small cell lung cancer, Seminars in Oncology, vol.29, issue.5 Suppl 14, pp.38-44, 2002.
DOI : 10.1053/sonc.2002.35646

C. Suarez, S. Pieren, M. Cariolat, L. Arn, S. Hoffmann et al., A VEGF-A splice variant defective for heparan sulfate and neuropilin-1 binding shows attenuated signaling through VEGFR-2, Cellular and Molecular Life Sciences, vol.63, issue.17, pp.2067-2077, 2006.
DOI : 10.1007/s00018-006-6254-9

D. Cameron, J. Brown, R. Dent, C. Jackisch, J. Mackey et al., Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial, The Lancet Oncology, vol.14, issue.10, pp.933-942, 2013.
DOI : 10.1016/S1470-2045(13)70335-8

A. Carrato, A. Swieboda-sadlej, M. Staszewska-skurczynska, R. Lim, L. Roman et al., Fluorouracil, Leucovorin, and Irinotecan Plus Either Sunitinib or Placebo in Metastatic Colorectal Cancer: A Randomized, Phase III Trial, Journal of Clinical Oncology, vol.31, issue.10, pp.1341-1347, 1930.
DOI : 10.1200/JCO.2012.45.1930

M. Caulet, T. Lecomte, O. Bouché, J. Rollin, V. Gouilleux-gruart et al., Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients, Clinical Pharmacokinetics, vol.108, issue.5, pp.1381-1394, 2016.
DOI : 10.1038/bjc.2013.79

L. Chelis, V. Souftas, K. Amarantidis, N. Xenidis, E. Chamalidou et al., Reversible Posterior Leukoencephalopathy Syndrome Induced by Pazopanib, BMC Cancer, vol.340, issue.Suppl, pp.1471-2407, 2012.
DOI : 10.1056/NEJM199906103402306

H. Chen, M. R. Modiano, J. W. Neal, J. R. Brahmer, J. R. Rigas et al., A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer, British Journal of Cancer, vol.19, issue.3, pp.602-608, 2014.
DOI : 10.1007/s11912-008-0013-z

N. Cho, S. Im, I. Park, K. Lee, M. Li et al., Breast Cancer: Early Prediction of Response to Neoadjuvant Chemotherapy Using Parametric Response Maps for MR Imaging, Radiology, vol.272, issue.2, pp.385-396, 2014.
DOI : 10.1148/radiol.14131332

H. Choi, C. Charnsangavej, S. C. Faria, H. A. Macapinlac, M. A. Burgess et al., Correlation of Computed Tomography and Positron Emission Tomography in Patients With Metastatic Gastrointestinal Stromal Tumor Treated at a Single Institution With Imatinib Mesylate: Proposal of New Computed Tomography Response Criteria, Journal of Clinical Oncology, vol.25, issue.13, pp.1753-1759, 2007.
DOI : 10.1200/JCO.2006.07.3049

T. K. Choueiri, B. Escudier, T. Powles, N. M. Tannir, P. N. Mainwaring et al., Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial, The Lancet Oncology, vol.17, issue.7, pp.917-927, 2016.
DOI : 10.1016/S1470-2045(16)30107-3

T. K. Choueiri, S. Halabi, B. L. Sanford, O. Hahn, M. D. Michaelson et al., Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial, Journal of Clinical Oncology, vol.35, issue.6, pp.591-597, 2017.
DOI : 10.1200/JCO.2016.70.7398

C. Christodoulou, A. Pervena, G. Klouvas, E. Galani, M. E. Falagas et al., Combination of Bisphosphonates and Antiangiogenic Factors Induces Osteonecrosis of the Jaw More Frequently than Bisphosphonates Alone, Oncology, vol.76, issue.3, pp.209-211, 2009.
DOI : 10.1159/000201931

J. P. Crown, V. Diéras, E. Staroslawska, D. A. Yardley, T. Bachelot et al., Phase III Trial of Sunitinib in Combination With Capecitabine Versus Capecitabine Monotherapy for the Treatment of Patients With Pretreated Metastatic Breast Cancer, Journal of Clinical Oncology, vol.31, issue.23, pp.2870-2878, 2013.
DOI : 10.1200/JCO.2012.43.3391

R. Cumurciuc, L. Martinez-almoyna, C. Henry, H. Husson, and T. De-broucker, Posterior reversible encephalopathy syndrome during sunitinib therapy, Revue Neurologique, vol.164, issue.6-7, pp.605-607, 2008.
DOI : 10.1016/j.neurol.2008.03.007

S. E. Dahlberg, A. B. Sandler, J. R. Brahmer, J. H. Schiller, and D. H. Johnson, Clinical Course of Advanced Non???Small-Cell Lung Cancer Patients Experiencing Hypertension During Treatment With Bevacizumab in Combination With Carboplatin and Paclitaxel on ECOG 4599, Journal of Clinical Oncology, vol.28, issue.6, pp.949-954, 2010.
DOI : 10.1200/JCO.2009.25.4482

M. I. Davis, J. P. Hunt, S. Herrgard, P. Ciceri, L. M. Wodicka et al., Comprehensive analysis of kinase inhibitor selectivity, Nature Biotechnology, vol.114, issue.11, pp.1046-1051, 1990.
DOI : 10.1016/j.chembiol.2011.05.010

G. D. Demetri, A. T. Van-oosterom, C. R. Garrett, M. E. Blackstein, M. H. Shah et al., Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial, The Lancet, vol.368, issue.9544, pp.1329-1338, 2006.
DOI : 10.1016/S0140-6736(06)69446-4

G. D. Demetri, P. Reichardt, Y. Kang, J. Blay, P. Rutkowski et al., GRID study investigators, 2013. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial, Lancet Lond. Engl, vol.38112, pp.295-302

I. M. Desar, D. M. Burger, Q. G. Van-hoesel, J. H. Beijnen, C. M. Van-herpen et al., Pharmacokinetics of sunitinib in an obese patient with a GIST, Annals of Oncology, vol.20, issue.3, pp.599-600, 2009.
DOI : 10.1093/annonc/mdn779

M. H. Diekstra, H. J. Klümpen, M. P. Lolkema, H. Yu, J. S. Kloth et al., Association Analysis of Genetic Polymorphisms in Genes Related to Sunitinib Pharmacokinetics, Specifically Clearance of Sunitinib and SU12662, Clinical Pharmacology & Therapeutics, vol.81, issue.1, pp.81-89, 2014.
DOI : 10.1086/519795

F. Donskov, M. D. Michaelson, I. Puzanov, M. P. Davis, G. A. Bjarnason et al., Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients, British Journal of Cancer, vol.62, issue.11, pp.1571-1580, 2015.
DOI : 10.1093/annonc/mdr047

A. Dowlati, R. Gray, A. B. Sandler, J. H. Schiller, and D. H. Johnson, Cell Adhesion Molecules, Vascular Endothelial Growth Factor, and Basic Fibroblast Growth Factor in Patients with Non-Small Cell Lung Cancer Treated with Chemotherapy with or without Bevacizumab--an Eastern Cooperative Oncology Group Study, Clinical Cancer Research, vol.14, issue.5, pp.1407-1412, 2008.
DOI : 10.1158/1078-0432.CCR-07-1154

O. Dudeck, M. Zeile, P. Reichardt, and D. Pink, Comparison of RECIST and Choi criteria for computed tomographic response evaluation in patients with advanced gastrointestinal stromal tumor treated with sunitinib, Annals of Oncology, vol.22, issue.8, pp.1828-1833, 2011.
DOI : 10.1093/annonc/mdq696

J. W. De-groot, T. P. Links, and W. T. Van-der-graaf, Tyrosine kinase inhibitors causing hypothyroidism in a patient on levothyroxine, Annals of Oncology, vol.17, issue.11, pp.1719-1720, 2006.
DOI : 10.1093/annonc/mdl112

N. De-jesus-gonzalez, E. Robinson, J. Moslehi, and B. D. Humphreys, Management of antiangiogenic therapy-induced hypertension. Hypertens. Dallas Tex, pp.607-615, 1979.

R. Elisei, M. J. Schlumberger, S. P. Müller, P. Schöffski, M. S. Brose et al., Cabozantinib in Progressive Medullary Thyroid Cancer, Journal of Clinical Oncology, vol.31, issue.29, pp.3639-3646, 2013.
DOI : 10.1200/JCO.2012.48.4659

L. Erdem, E. Giovannetti, L. G. Leon, R. Honeywell, and G. J. Peters, Polymorphisms to Predict Outcome to the Tyrosine Kinase Inhibitors Gefitinib, Erlotinib, Sorafenib and Sunitinib, Current Topics in Medicinal Chemistry, vol.12, issue.15, pp.1649-1659, 2012.
DOI : 10.2174/156802612803531333

V. Eremina, J. A. Jefferson, J. Kowalewska, H. Hochster, M. Haas et al., VEGF Inhibition and Renal Thrombotic Microangiopathy, New England Journal of Medicine, vol.358, issue.11, pp.1129-1136, 2008.
DOI : 10.1056/NEJMoa0707330

B. Escudier, T. Eisen, W. M. Stadler, C. Szczylik, S. Oudard et al., Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma, New England Journal of Medicine, vol.356, issue.2, pp.125-134, 2007.
DOI : 10.1056/NEJMoa060655

B. Escudier, A. Pluzanska, P. Koralewski, A. Ravaud, S. Bracarda et al., Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial, The Lancet, vol.370, issue.9605, pp.2103-2111, 2007.
DOI : 10.1016/S0140-6736(07)61904-7

B. Escudier, J. Roigas, S. Gillessen, U. Harmenberg, S. Srinivas et al., Phase II Study of Sunitinib Administered in a Continuous Once-Daily Dosing Regimen in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma, Journal of Clinical Oncology, vol.27, issue.25, pp.4068-4075, 2009.
DOI : 10.1200/JCO.2008.20.5476

B. Escudier, C. Porta, P. Bono, T. Powles, T. Eisen et al., Randomized, Controlled, Double-Blind, Cross-Over Trial Assessing Treatment Preference for Pazopanib Versus Sunitinib in Patients With Metastatic Renal Cell Carcinoma: PISCES Study, Journal of Clinical Oncology, vol.32, issue.14, pp.1412-1418, 2014.
DOI : 10.1200/JCO.2013.50.8267

P. Fallahi, S. M. Ferrari, R. Vita, D. Domenicantonio, A. Corrado et al., Thyroid dysfunctions induced by tyrosine kinase inhibitors, Expert Opinion on Drug Safety, vol.11, pp.723-733, 2014.
DOI : 10.1038/ncponc0998

K. T. Flaherty, S. J. Lee, F. Zhao, L. M. Schuchter, L. Flaherty et al., Phase III Trial of Carboplatin and Paclitaxel With or Without Sorafenib in Metastatic Melanoma, Journal of Clinical Oncology, vol.31, issue.3, pp.373-379, 2013.
DOI : 10.1200/JCO.2012.42.1529

J. Folkman, E. Merler, C. Abernathy, and G. Williams, ISOLATION OF A TUMOR FACTOR RESPONSIBLE FOR ANGIOGENESIS, Journal of Experimental Medicine, vol.133, issue.2, pp.275-288, 1971.
DOI : 10.1084/jem.133.2.275

I. J. Frew and H. Moch, A Clearer View of the Molecular Complexity of Clear Cell Renal Cell Carcinoma, Annual Review of Pathology: Mechanisms of Disease, vol.10, issue.1, pp.263-289, 2015.
DOI : 10.1146/annurev-pathol-012414-040306

J. Ge, B. Tan, Y. Chen, L. Yang, X. Peng et al., Interaction of green tea polyphenol epigallocatechin-3-gallate with sunitinib: potential risk of diminished sunitinib bioavailability, Journal of Molecular Medicine, vol.15, issue.6, pp.595-602, 2011.
DOI : 10.1158/1078-0432.CCR-09-0717

P. Ghatalia, C. J. Morgan, Y. Je, P. L. Nguyen, Q. Trinh et al., Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors, Critical Reviews in Oncology/Hematology, vol.94, issue.2, pp.228-237, 2015.
DOI : 10.1016/j.critrevonc.2014.12.008

M. R. Gilbert, J. J. Dignam, T. S. Armstrong, J. S. Wefel, D. T. Blumenthal et al., A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma, New England Journal of Medicine, vol.370, issue.8, pp.699-708, 2014.
DOI : 10.1056/NEJMoa1308573

A. Gonçalves, M. Gilabert, E. François, L. Dahan, H. Perrier et al., BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer, Annals of Oncology, vol.23, issue.11, pp.2799-2805, 2012.
DOI : 10.1093/annonc/mds135

A. Gopal, R. A. Flores, M. E. Lacouture, and S. Wu, Differential effects of bevacizumab on the risk of hand-foot syndrome associated with cytotoxic chemotherapy: an updated meta-analysis, J. Clin. Oncol, p.31, 2013.

A. Grothey, E. Van-cutsem, A. Sobrero, S. Siena, A. Falcone et al., CORRECT Study Group, 2013. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebocontrolled , phase 3 trial, Lancet Lond. Engl, vol.38112, pp.303-312

M. Guan, Y. Zhou, J. Sun, and S. Chen, Adverse Events of Monoclonal Antibodies Used for Cancer Therapy, BioMed Research International, vol.21, issue.1, 2015.
DOI : 10.1158/1078-0432.CCR-12-2982

T. Guo, M. Hajdu, N. P. Agaram, H. Shinoda, D. Veach et al., Mechanisms of Sunitinib Resistance in Gastrointestinal Stromal Tumors Harboring KITAY502-3ins Mutation: An In vitro Mutagenesis Screen for Drug Resistance, Clinical Cancer Research, vol.15, issue.22, 2009.
DOI : 10.1158/1078-0432.CCR-09-1315

J. O. Hadj, R. D. Braven, C. Tillier, H. M. Schrijver, H. M. Verheul et al., Reversible posterior leukoencephalopathy syndrome during sunitinib therapy for metastatic renal cell carcinoma, Oncol. Lett, vol.3, pp.1293-1296, 2012.

O. M. Hahn, C. Yang, M. Medved, G. Karczmar, E. Kistner et al., Dynamic Contrast-Enhanced Magnetic Resonance Imaging Pharmacodynamic Biomarker Study of Sorafenib in Metastatic Renal Carcinoma, Journal of Clinical Oncology, vol.26, issue.28, pp.4572-4578, 2008.
DOI : 10.1200/JCO.2007.15.5655

K. Han, J. Jin, M. Maia, J. Lowe, M. A. Sersch et al., Lower Exposure and Faster Clearance of Bevacizumab in Gastric Cancer and the Impact of Patient Variables: Analysis of Individual Data from AVAGAST Phase III Trial, The AAPS Journal, vol.16, issue.5, pp.1056-1063, 2014.
DOI : 10.1208/s12248-014-9631-6

K. Han, T. Peyret, M. Marchand, A. Quartino, N. H. Gosselin et al., Population pharmacokinetics of bevacizumab in cancer patients with external validation, Cancer Chemotherapy and Pharmacology, vol.76, issue.3, pp.341-351, 2016.
DOI : 10.1016/j.lungcan.2011.12.005

D. Hanahan and J. Folkman, Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis, Cell, vol.86, issue.3, pp.353-364, 1996.
DOI : 10.1016/S0092-8674(00)80108-7

D. Hanahan and R. A. Weinberg, The Hallmarks of Cancer, Cell, vol.100, issue.1, pp.57-70, 2000.
DOI : 10.1016/S0092-8674(00)81683-9

S. Hapani, A. Sher, D. Chu, and S. Wu, Increased Risk of Serious Hemorrhage with Bevacizumab in Cancer Patients: A Meta-Analysis, Oncology, vol.79, issue.1-2, pp.27-38, 2010.
DOI : 10.1159/000314980

A. Hauschild, S. S. Agarwala, U. Trefzer, D. Hogg, C. Robert et al., Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma, Journal of Clinical Oncology, vol.27, issue.17, pp.2823-2830, 2009.
DOI : 10.1200/JCO.2007.15.7636

V. Heinemann, L. F. Von-weikersthal, T. Decker, A. Kiani, U. Vehling-kaiser et al., FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial, The Lancet Oncology, vol.15, issue.10, pp.1065-1075, 2014.
DOI : 10.1016/S1470-2045(14)70330-4

M. Herbrink, B. Nuijen, J. H. Schellens, and J. H. Beijnen, Variability in bioavailability of small molecular tyrosine kinase inhibitors, Cancer Treatment Reviews, vol.41, issue.5, pp.412-422, 2015.
DOI : 10.1016/j.ctrv.2015.03.005

D. J. Hicklin and L. M. Ellis, Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis, Journal of Clinical Oncology, vol.23, issue.5, pp.1011-1027, 2005.
DOI : 10.1200/JCO.2005.06.081

R. A. Hilger, H. Richly, M. Grubert, S. Kredtke, D. Thyssen et al., Pharmacokinetics of sorafenib in patients with renal impairment undergoing hemodialysis, Int. Journal of Clinical Pharmacology and Therapeutics, vol.47, issue.01, pp.61-64, 2009.
DOI : 10.5414/CPP47061

J. Holash, S. Davis, N. Papadopoulos, S. D. Croll, L. Ho et al., VEGF-Trap: A VEGF blocker with potent antitumor effects, Proceedings of the National Academy of Sciences, vol.42, issue.10, pp.11393-11398, 2002.
DOI : 10.1172/JCI200213776

B. E. Houk, C. L. Bello, B. Poland, L. S. Rosen, G. D. Demetri et al., Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic, 2010.

H. Hurwitz, L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hainsworth et al., Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer, New England Journal of Medicine, vol.350, issue.23, pp.2335-2342, 2004.
DOI : 10.1056/NEJMoa032691

H. I. Hurwitz, L. B. Saltz, E. Van-cutsem, J. Cassidy, J. Wiedemann et al., Venous Thromboembolic Events With Chemotherapy Plus Bevacizumab: A Pooled Analysis of Patients in Randomized Phase II and III Studies, Journal of Clinical Oncology, vol.29, issue.13, pp.1757-1764, 2011.
DOI : 10.1200/JCO.2010.32.3220

H. I. Hurwitz, N. C. Tebbutt, F. Kabbinavar, B. J. Giantonio, Z. Guan et al., Efficacy and Safety of Bevacizumab in Metastatic Colorectal Cancer: Pooled Analysis From Seven Randomized Controlled Trials, The Oncologist, vol.18, issue.9, pp.1004-10122013, 2013.
DOI : 10.1634/theoncologist.2013-0107

T. E. Hutson, I. D. Davis, J. H. Machiels, D. Souza, P. L. Rottey et al., Efficacy and Safety of Pazopanib in Patients With Metastatic Renal Cell Carcinoma, Journal of Clinical Oncology, vol.28, issue.3, pp.475-480, 2010.
DOI : 10.1200/JCO.2008.21.6994

H. Izzedine, C. Massard, J. P. Spano, F. Goldwasser, D. Khayat et al., VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management, European Journal of Cancer, vol.46, issue.2, pp.439-448, 1990.
DOI : 10.1016/j.ejca.2009.11.001

R. K. Jain, D. G. Duda, C. G. Willett, D. V. Sahani, A. X. Zhu et al., Biomarkers of response and resistance to antiangiogenic therapy, Nature Reviews Clinical Oncology, vol.14, issue.6, pp.327-338, 2009.
DOI : 10.1056/NEJM197111182852108

R. K. Jain, Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy, Science, vol.307, issue.5706, pp.58-62, 2005.
DOI : 10.1126/science.1104819

G. W. Jean, R. M. Mani, A. Jaffry, and S. A. Khan, Toxic Effects of Sorafenib in Patients With Differentiated Thyroid Carcinoma Compared With Other Cancers, JAMA Oncology, vol.2, issue.4, pp.529-534, 2016.
DOI : 10.1001/jamaoncol.2015.5927

D. Josephs, T. E. Hutson, C. L. Cowey, L. M. Pickering, J. M. Larkin et al., Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis, BJU International, vol.41, issue.8, pp.1279-1283, 2011.
DOI : 10.1016/S0735-1097(03)00163-3

F. Kabbinavar, H. I. Hurwitz, L. Fehrenbacher, N. J. Meropol, W. F. Novotny et al., Phase II, Randomized Trial Comparing Bevacizumab Plus Fluorouracil (FU)/Leucovorin (LV) With FU/LV Alone in Patients With Metastatic Colorectal Cancer, Journal of Clinical Oncology, vol.21, issue.1, pp.60-65, 2003.
DOI : 10.1200/JCO.2003.10.066

T. Kamba, B. Y. Tam, H. Hashizume, A. Haskell, B. Sennino et al., VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature, AJP: Heart and Circulatory Physiology, vol.290, issue.2, pp.560-576, 2005.
DOI : 10.1152/ajpheart.00133.2005

T. Kangsamaksin, A. Murtomaki, N. M. Kofler, H. Cuervo, R. A. Chaudhri et al., NOTCH Decoys That Selectively Block DLL/NOTCH or JAG/NOTCH Disrupt Angiogenesis by Unique Mechanisms to Inhibit Tumor Growth, Cancer Discovery, vol.5, issue.2, pp.182-197, 2015.
DOI : 10.1158/2159-8290.CD-14-0650

P. I. Karakiewicz, L. Nott, A. Joshi, G. Kannourakis, J. Tarazi et al., Evaluation of response from axitinib per Response Evaluation Criteria in Solid Tumors versus Choi criteria in previously treated patients with metastatic renal cell carcinoma. OncoTargets Ther, pp.2855-2863, 2016.

R. J. Keizer, A. D. Huitema, J. H. Schellens, and J. H. Beijnen, Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies, Clinical Pharmacokinetics, vol.5, issue.8, pp.493-507, 2010.
DOI : 10.4049/jimmunol.178.8.5390

R. S. Kerbel, Tumor Angiogenesis, New England Journal of Medicine, vol.358, issue.19, pp.2039-2049, 2008.
DOI : 10.1056/NEJMra0706596

L. Khoja, G. Kumaran, Y. K. Zee, N. Murukesh, R. Swindell et al., Evaluation of Hypertension and Proteinuria as Markers of Efficacy in Antiangiogenic Therapy for Metastatic Colorectal Cancer, Journal of Clinical Gastroenterology, vol.48, pp.430-434, 2014.
DOI : 10.1097/MCG.0b013e3182a8804c

R. Khosravan, M. Toh, M. Garrett, L. Fargue, J. Ni et al., Pharmacokinetics and Safety of Sunitinib Malate in Subjects With Impaired Renal Function, The Journal of Clinical Pharmacology, vol.17, issue.suppl 9, pp.472-481, 2010.
DOI : 10.1097/MNH.0b013e3283136732

H. R. Kim, H. S. Park, W. S. Kwon, J. H. Lee, Y. Tanigawara et al., Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients, Cancer Chemotherapy and Pharmacology, vol.17, issue.4, pp.825-835, 2013.
DOI : 10.1158/1078-0432.CCR-10-1828

H. Kim, K. S. Keene, D. B. Sarver, S. K. Lee, T. M. Beasley et al., Quantitative perfusion-and diffusion-weighted magnetic resonance imaging of gastrointestinal cancers treated with multikinase inhibitors: a pilot study, Gastrointest. Cancer Res. GCR, vol.7, pp.75-81, 2014.

K. M. Krajewski, M. Guo, A. D. Van-den-abbeele, J. Yap, N. Ramaiya et al., Comparison of Four Early Posttherapy Imaging Changes (EPTIC; RECIST 1.0, Tumor Shrinkage, Computed Tomography Tumor Density, Choi Criteria) in Assessing Outcome to Vascular Endothelial Growth Factor???Targeted Therapy in Patients With Advanced Renal Cell Carcinoma, European Urology, vol.59, issue.5, pp.856-862, 2011.
DOI : 10.1016/j.eururo.2011.01.038

T. N. Kreisl, L. Kim, K. Moore, P. Duic, C. Royce et al., Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma, Journal of Clinical Oncology, vol.27, issue.5, pp.740-745, 2009.
DOI : 10.1200/JCO.2008.16.3055

X. Lai, R. Xu, L. Yu-ping, and H. Yang, Risk of adverse events with bevacizumab addition to therapy in advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials. OncoTargets Ther, pp.2421-2428, 2016.

N. A. Lankheet, A. D. Huitema, H. Mallo, S. Adriaansz, J. B. Haanen et al., The effect of seasonal variation and secretion of sunitinib in sweat on the development of hand???foot syndrome, European Journal of Clinical Pharmacology, vol.30, issue.1, pp.2065-2072, 2013.
DOI : 10.1592/phco.30.1.52

S. Lankhorst, M. H. Kappers, J. H. Van-esch, F. M. Smedts, S. Sleijfer et al., Treatment of hypertension and renal injury induced by the angiogenesis inhibitor sunitinib: preclinical study, Hypertens. Dallas Tex, issue.64, pp.1282-1289, 1979.

M. Laruelle, B. Filleul, T. Duprez, and J. Machiels, Posterior Reversible Encephalopathy Syndrome Associated with Sorafenib and Successful Retreatment, Urologia Internationalis, 2016.
DOI : 10.1159/000443970

N. Lassau, L. Chami, B. Benatsou, P. Peronneau, and A. Roche, Dynamic contrastenhanced ultrasonography (DCE-US) with quantification of tumor perfusion: a new diagnostic tool to evaluate the early effects of antiangiogenic treatment, Eur. Radiol, pp.17-89, 2007.

N. Lassau, B. Coiffier, M. Kind, V. Vilgrain, J. Lacroix et al., Selection of an early biomarker for vascular normalization using dynamic contrast-enhanced ultrasonography to predict outcomes of metastatic patients treated with bevacizumab, Annals of Oncology, vol.27, issue.10, pp.1922-1928, 2016.
DOI : 10.1093/annonc/mdw280

L. León-mateos, J. Mosquera, A. Aparicio, and L. , Treatment of sunitinib-induced hypertension in solid tumor by nitric oxide donors, Redox Biology, vol.6, pp.421-425, 2015.
DOI : 10.1016/j.redox.2015.09.007

J. L. Lee, M. K. Kim, I. Park, J. Ahn, D. H. Lee et al., RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial, Annals of Oncology, vol.26, issue.11, pp.2300-2305, 2015.
DOI : 10.1093/annonc/mdv357

S. H. Lee, K. Hayano, A. X. Zhu, D. V. Sahani, and H. Yoshida, Dynamic Contrast-Enhanced MRI Kinetic Parameters as Prognostic Biomarkers for Prediction of Survival of Patient with Advanced Hepatocellular Carcinoma, Academic Radiology, vol.22, issue.11, pp.1344-1360, 2015.
DOI : 10.1016/j.acra.2015.05.012

H. J. Lemmens and J. Ingrande, Pharmacology and Obesity, International Anesthesiology Clinics, vol.51, issue.3, pp.52-66, 2013.
DOI : 10.1097/AIA.0b013e31829a4d56

Y. Li, S. Li, Y. Zhu, X. Liang, H. Meng et al., Incidence and Risk of Sorafenib-Induced Hypertension: A Systematic Review and Meta-Analysis, The Journal of Clinical Hypertension, vol.23, issue.5B, pp.177-185, 2014.
DOI : 10.1093/annonc/mds135

X. Li, R. G. Abramson, L. R. Arlinghaus, H. Kang, A. B. Chakravarthy et al., Multiparametric Magnetic Resonance Imaging for Predicting Pathological Response After the First Cycle of Neoadjuvant Chemotherapy in Breast Cancer, Investigative Radiology, vol.50, issue.4, pp.195-204, 2015.
DOI : 10.1097/RLI.0000000000000100

Z. Liang, J. Brooks, M. Willard, K. Liang, Y. Yoon et al., CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway, Biochemical and Biophysical Research Communications, vol.359, issue.3, pp.716-722, 2007.
DOI : 10.1016/j.bbrc.2007.05.182

A. D. Lipworth, C. Robert, and A. X. Zhu, Hand-Foot Syndrome (Hand-Foot Skin Reaction, Palmar-Plantar Erythrodysesthesia): Focus on Sorafenib and Sunitinib, Oncology, vol.77, issue.5, pp.257-271, 2009.
DOI : 10.1159/000258880

J. M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane et al., Sorafenib in Advanced Hepatocellular Carcinoma, SHARP Investigators Study Group Sorafenib in advanced hepatocellular carcinoma, pp.378-390, 2008.
DOI : 10.1056/NEJMoa0708857

G. Lombardi, F. Zustovich, P. Farina, P. Fiduccia, D. Puppa et al., Hypertension as a biomarker in patients with recurrent glioblastoma treated with antiangiogenic drugs, Anti-Cancer Drugs, vol.24, issue.1, pp.90-97, 2013.
DOI : 10.1097/CAD.0b013e32835aa5fd

R. Longo and G. Gasparini, Challenges for patient selection with VEGF inhibitors, Cancer Chemotherapy and Pharmacology, vol.6, issue.11, pp.151-170, 2007.
DOI : 10.1038/nrc1946

G. G. Malouf, R. Flippot, and D. Khayat, Therapeutic Strategies for Patients With Metastatic Renal Cell Carcinoma in Whom First-Line Vascular Endothelial Growth Factor Receptor???Directed Therapies Fail, Journal of Oncology Practice, vol.12, issue.5, pp.412-420, 2016.
DOI : 10.1200/JOP.2016.011809

M. L. Marinovich, F. Sardanelli, S. Ciatto, E. Mamounas, M. Brennan et al., Early prediction of pathologic response to neoadjuvant therapy in breast cancer: Systematic review of the accuracy of MRI, The Breast, vol.21, issue.5, pp.669-677, 2012.
DOI : 10.1016/j.breast.2012.07.006

C. Marth, I. Vergote, G. Scambia, W. Oberaigner, A. Clamp et al., ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer, European Journal of Cancer, vol.70, issue.70, pp.1990-111
DOI : 10.1016/j.ejca.2016.09.004

B. Mclellan, F. Ciardiello, M. E. Lacouture, S. Segaert, and E. Van-cutsem, Regorafenib-associated hand???foot skin reaction: practical advice on diagnosis, prevention, and management, Annals of Oncology, vol.26, issue.10, pp.2017-2026, 2015.
DOI : 10.1093/annonc/mdv244

C. Messiou, M. Orton, J. E. Ang, D. J. Collins, V. A. Morgan et al., Advanced Solid Tumors Treated with Cediranib: Comparison of Dynamic Contrast-enhanced MR Imaging and CT as Markers of Vascular Activity, Radiology, vol.265, issue.2, pp.426-436, 2012.
DOI : 10.1148/radiol.12112565

D. W. Miles, A. Chan, L. Y. Dirix, J. Cortés, X. Pivot et al., Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2???Negative Metastatic Breast Cancer, Journal of Clinical Oncology, vol.28, issue.20, pp.3239-3247, 2010.
DOI : 10.1200/JCO.2008.21.6457

URL : https://hal.archives-ouvertes.fr/inserm-00508083

K. Miller, M. Wang, J. Gralow, M. Dickler, M. Cobleigh et al., Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer, New England Journal of Medicine, vol.357, issue.26, pp.2666-2676, 2007.
DOI : 10.1056/NEJMoa072113

O. Mir, R. Coriat, P. Boudou-rouquette, J. P. Durand, and F. Goldwasser, Sorafenibinduced diarrhea and hypophosphatemia: mechanisms and therapeutic implications, 2012.

O. Mir, R. Coriat, S. Ropert, L. Cabanes, B. Blanchet et al., Treatment of bevacizumab-induced hypertension by amlodipine, Investigational New Drugs, vol.28, issue.2, pp.702-707, 2012.
DOI : 10.1291/hypres.28.147

O. Mir, T. Brodowicz, A. Italiano, J. Wallet, J. Blay et al., Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial, The Lancet Oncology, vol.17, issue.12, pp.1732-1742, 2016.
DOI : 10.1016/S1470-2045(16)30507-1

B. J. Monk, A. Poveda, I. Vergote, F. Raspagliesi, K. Fujiwara et al., Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2, Gynecologic Oncology, vol.143, issue.1, pp.27-34, 2016.
DOI : 10.1016/j.ygyno.2016.07.112

B. Morgan, A. L. Thomas, J. Drevs, J. Hennig, M. Buchert et al., Dynamic Contrast-Enhanced Magnetic Resonance Imaging As a Biomarker for the Pharmacological Response of PTK787/ZK 222584, an Inhibitor of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, in Patients With Advanced Colorectal Cancer and Liver Metastases: Results From Two Phase I Studies, Journal of Clinical Oncology, vol.21, issue.21, pp.3955-3964, 2003.
DOI : 10.1200/JCO.2003.08.092

R. J. Motzer, T. E. Hutson, P. Tomczak, M. D. Michaelson, R. M. Bukowski et al., Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma, New England Journal of Medicine, vol.356, issue.2, pp.115-124, 2007.
DOI : 10.1056/NEJMoa065044

R. J. Motzer, T. E. Hutson, M. R. Olsen, G. R. Hudes, J. M. Burke et al., Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First-Line Therapy for Advanced Renal Cell Carcinoma, Journal of Clinical Oncology, vol.30, issue.12, pp.1371-1377, 2012.
DOI : 10.1200/JCO.2011.36.4133

R. J. Motzer, T. E. Hutson, D. Cella, J. Reeves, R. Hawkins et al., Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma, New England Journal of Medicine, vol.369, issue.8, pp.722-731, 2013.
DOI : 10.1056/NEJMoa1303989

R. J. Motzer, T. E. Hutson, L. Mccann, K. Deen, and T. K. Choueiri, Overall Survival in Renal-Cell Carcinoma with Pazopanib versus Sunitinib, New England Journal of Medicine, vol.370, issue.18, pp.1769-1770, 2014.
DOI : 10.1056/NEJMc1400731

R. J. Motzer, Perspective: what next for treatment? Nature 537, S111, 2016.

N. Murukesh, C. Dive, and G. C. Jayson, Biomarkers of angiogenesis and their role in the development of VEGF inhibitors, British Journal of Cancer, vol.26, issue.1, pp.8-18, 2010.
DOI : 10.1002/cyto.a.20364

S. R. Nalluri, D. Chu, R. Keresztes, X. Zhu, and S. Wu, Risk of Venous Thromboembolism With the Angiogenesis Inhibitor Bevacizumab in Cancer Patients, JAMA, vol.300, issue.19, pp.2277-2285656, 2008.
DOI : 10.1001/jama.2008.656

B. W. Newsome and M. S. Ernstoff, The clinical pharmacology of therapeutic monoclonal antibodies in the treatment of malignancy; have the magic bullets arrived?, British Journal of Clinical Pharmacology, vol.7, issue.1, pp.6-19, 2008.
DOI : 10.1056/NEJMoa063842

A. Ohtsu, M. A. Shah, E. Van-cutsem, S. Y. Rha, A. Sawaki et al., Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study, Journal of Clinical Oncology, vol.29, issue.30, pp.3968-3976, 2011.
DOI : 10.1200/JCO.2011.36.2236

N. Pécuchet, C. Lebbe, O. Mir, B. Billemont, B. Blanchet et al., Sorafenib in advanced melanoma: a critical role for pharmacokinetics?, British Journal of Cancer, vol.29, issue.3, pp.455-461, 2012.
DOI : 10.1158/0008-5472.CAN-04-1443

J. Pander, H. J. Guchelaar, and H. Gelderblom, Pharmacogenetics of small-molecule tyrosine kinase inhibitors: optimizing the magic bullet, Curr. Opin. Mol. Ther, vol.12, pp.654-661, 2010.

N. Papadopoulos, J. Martin, Q. Ruan, A. Rafique, M. P. Rosconi et al., Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab, Angiogenesis, vol.28, issue.281, pp.171-185, 2012.
DOI : 10.1200/JCO.2009.24.8252

T. V. Patel, J. A. Morgan, G. D. Demetri, S. George, R. G. Maki et al., A Preeclampsia-like Syndrome Characterized by Reversible Hypertension and Proteinuria Induced by the Multitargeted Kinase Inhibitors Sunitinib and Sorafenib, JNCI Journal of the National Cancer Institute, vol.100, issue.4, pp.282-284, 2008.
DOI : 10.1093/jnci/djm311

E. Patras-de-campaigno, E. Bondon-guitton, G. Laurent, F. Montastruc, J. Montastruc et al., Identification of cellular targets involved in cardiac failure caused by PKI in oncology: an approach combining pharmacovigilance and pharmacodynamics, British Journal of Clinical Pharmacology, vol.7, issue.Suppl. 374, pp.1544-1555, 2017.
DOI : 10.1038/nrc2106

R. T. Poon, S. T. Fan, and J. Wong, Clinical Implications of Circulating Angiogenic Factors in Cancer Patients, Journal of Clinical Oncology, vol.19, issue.4, pp.1207-1225, 2001.
DOI : 10.1200/JCO.2001.19.4.1207

R. Porta, R. Borea, A. Coelho, S. Khan, A. Araújo et al., FGFR a promising druggable target in cancer: Molecular biology and new drugs, Critical Reviews in Oncology/Hematology, vol.113, pp.256-267, 2017.
DOI : 10.1016/j.critrevonc.2017.02.018

T. Powles, S. Bracarda, M. Chen, E. Norry, N. Compton et al., Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: A systematic review and meta-analysis of clinical trials in advanced cancer patients, European Journal of Cancer, vol.51, issue.10, pp.1293-1302, 2015.
DOI : 10.1016/j.ejca.2015.03.019

M. Presta, P. Dell-'era, S. Mitola, E. Moroni, R. Ronca et al., Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis, Cytokine & Growth Factor Reviews, vol.16, issue.2, pp.159-178, 2005.
DOI : 10.1016/j.cytogfr.2005.01.004

W. Qi, S. Fu, Q. Zhang, and X. Guo, Bevacizumab Increases the Risk of Severe Congestive Heart Failure in Cancer Patients: An Up-to-Date Meta-Analysis with a Focus on Different Subgroups, Clinical Drug Investigation, vol.29, issue.25, pp.681-690, 2014.
DOI : 10.1111/bcp.12387

W. Qi, Z. Shen, L. Tang, and Y. Yao, Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials, British Journal of Clinical Pharmacology, vol.120, issue.4, pp.748-762, 2014.
DOI : 10.1172/JCI39434

M. Reck, R. Kaiser, A. Mellemgaard, J. Douillard, S. Orlov et al., LUME-Lung 1 Study Group, 2014. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial, Lancet Oncol, vol.1513, pp.143-155

B. I. Rini, I. Tamaskar, P. Shaheen, R. Salas, J. Garcia et al., Hypothyroidism in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib, JNCI: Journal of the National Cancer Institute, vol.99, issue.1, pp.81-83, 2007.
DOI : 10.1093/jnci/djk008

B. I. Rini, S. Halabi, J. E. Rosenberg, W. M. Stadler, D. A. Vaena et al., Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206, Journal of Clinical Oncology, vol.28, issue.13, pp.2137-2143, 2010.
DOI : 10.1200/JCO.2009.26.5561

B. I. Rini, B. Escudier, P. Tomczak, A. Kaprin, C. Szczylik et al., Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial, The Lancet, vol.378, issue.9807, pp.1931-1939, 2011.
DOI : 10.1016/S0140-6736(11)61613-9

B. I. Rini, B. Melichar, T. Ueda, V. Grünwald, M. N. Fishman et al., Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial, The Lancet Oncology, vol.14, issue.12, pp.1233-1242, 2013.
DOI : 10.1016/S1470-2045(13)70464-9

N. J. Robert, V. Diéras, J. Glaspy, A. M. Brufsky, I. Bondarenko et al., RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2???Negative, Locally Recurrent or Metastatic Breast Cancer, Journal of Clinical Oncology, vol.29, issue.10, pp.1252-1260, 2011.
DOI : 10.1200/JCO.2010.28.0982

S. P. Robinson, D. J. Mcintyre, D. Checkley, J. J. Tessier, F. A. Howe et al., Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging, British Journal of Cancer, vol.77, issue.Suppl 1, pp.1592-1597, 2003.
DOI : 10.1016/0304-4165(82)90333-6

A. Rocha, I. Azevedo, and R. Soares, Anti-angiogenic effects of imatinib target smooth muscle cells but not endothelial cells, Angiogenesis, vol.64, issue.6, pp.279-286, 2007.
DOI : 10.1007/s10456-007-9080-2

R. Ronca, A. Giacomini, M. Rusnati, and M. Presta, The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis, Expert Opinion on Therapeutic Targets, vol.61, issue.12, pp.1361-1377, 2015.
DOI : 10.1038/nrd2792

M. Ronot, M. Bouattour, J. Wassermann, O. Bruno, C. Dreyer et al., Alternative Response Criteria (Choi, European Association for the Study of the Liver, and Modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in Patients With Advanced Hepatocellular Carcinoma Treated With Sorafenib, The Oncologist, vol.19, issue.4, pp.394-4022013, 2014.
DOI : 10.1634/theoncologist.2013-0114

R. Roskoski, Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas, Pharmacological Research, vol.120, pp.116-132, 2017.
DOI : 10.1016/j.phrs.2017.03.010

J. R. Rossari, O. Metzger-filho, M. Paesmans, K. S. Saini, A. Gennari et al., Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence, Journal of Oncology, vol.35, issue.1, 2012.
DOI : 10.2165/11595910-000000000-00000

B. Rousseau, E. Kempf, G. Desamericq, E. Boissier, M. Chaubet-houdu et al., First-line antiangiogenics for metastatic renal cell carcinoma: A systematic review and network meta-analysis, Critical Reviews in Oncology/Hematology, vol.107, pp.44-53, 2016.
DOI : 10.1016/j.critrevonc.2016.08.012

A. Rowland, M. Van-dyk, A. A. Mangoni, J. O. Miners, R. A. Mckinnon et al., Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing inter-individual variability in exposure, Expert Opinion on Drug Metabolism & Toxicology, vol.66, issue.1, pp.31-49, 2017.
DOI : 10.21037/tcr.2016.05.19

J. Ruan, M. Luo, C. Wang, L. Fan, S. N. Yang et al., Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes, Blood, vol.121, issue.26, pp.5192-5202, 2013.
DOI : 10.1182/blood-2013-03-490763

J. Salem, E. Bruguiere, L. Iserin, A. Guiochon-mantel, and P. Plouin, Hypertension and aortorenal disease in Alagille syndrome, Journal of Hypertension, vol.30, issue.7, pp.1300-1306, 2012.
DOI : 10.1097/HJH.0b013e3283531e1f

J. Salem, J. Alexandre, A. Bachelot, and C. Funck-brentano, Influence of steroid hormones on ventricular repolarization, Pharmacology & Therapeutics, vol.167, pp.38-47, 2016.
DOI : 10.1016/j.pharmthera.2016.07.005

URL : https://hal.archives-ouvertes.fr/hal-01393416

G. Scagliotti, S. Novello, J. Von-pawel, M. Reck, J. R. Pereira et al., Phase III Study of Carboplatin and Paclitaxel Alone or With Sorafenib in Advanced Non???Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.28, issue.11, pp.1835-1842, 2010.
DOI : 10.1200/JCO.2009.26.1321

F. A. Scappaticci, L. Fehrenbacher, T. Cartwright, J. D. Hainsworth, W. Heim et al., Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab, Journal of Surgical Oncology, vol.50, issue.3, pp.173-180, 2005.
DOI : 10.1007/978-1-4899-4475-7

M. Scartozzi, L. Faloppi, G. Svegliati-baroni, C. Loretelli, F. Piscaglia et al., VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: The ALICE-1 study, International Journal of Cancer, vol.14, issue.Suppl 3, pp.1247-1256, 2014.
DOI : 10.2337/diabetes.51.5.1635

M. Schlumberger, M. Tahara, L. J. Wirth, B. Robinson, M. S. Brose et al., Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer, New England Journal of Medicine, vol.372, issue.7, pp.621-630, 2015.
DOI : 10.1056/NEJMoa1406470

N. Schmidt, V. Hess, T. Zumbrunn, C. Rothermundt, G. Bongartz et al., Choi response criteria for prediction of survival in patients with metastatic renal cell carcinoma treated with anti-angiogenic therapies, European Radiology, vol.7, pp.632-639, 2013.
DOI : 10.1016/S1076-6332(00)80632-7

B. P. Schneider, M. Wang, M. Radovich, G. W. Sledge, S. Badve et al., Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100, Journal of Clinical Oncology, vol.26, issue.28, pp.4672-4678, 2008.
DOI : 10.1200/JCO.2008.16.1612

E. L. Schwartz, Antivascular Actions of Microtubule-Binding Drugs, Clinical Cancer Research, vol.15, issue.8, pp.2594-2601, 2009.
DOI : 10.1158/1078-0432.CCR-08-2710

K. Sharma and J. R. Marcus, Bevacizumab and Wound-Healing Complications, Annals of Plastic Surgery, vol.71, issue.4, pp.434-440, 2013.
DOI : 10.1097/SAP.0b013e31824e5e57

M. Shibuya, Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti- and Pro-Angiogenic Therapies, Genes & Cancer, vol.2, issue.12, pp.1097-1105, 2011.
DOI : 10.1177/1947601911423031

V. Sibaud, L. Lamant, V. Maisongrosse, and J. Delord, Effets ind??sirables cutan??s des inhibiteurs de BRAF??: revue syst??matique, Annales de Dermatologie et de V??n??r??ologie, vol.140, issue.8-9, pp.510-520, 2013.
DOI : 10.1016/j.annder.2013.02.031

S. Singer, C. Grommes, A. S. Reiner, M. K. Rosenblum, and L. M. Deangelis, Posterior Reversible Encephalopathy Syndrome in Patients With Cancer, The Oncologist, vol.20, issue.7, pp.806-811, 2015.
DOI : 10.1634/theoncologist.2014-0149

T. Smidt-hansen, T. B. Folkmar, K. Fode, M. Agerbaek, and F. Donskov, Combination of Zoledronic Acid and Targeted Therapy Is Active But May Induce Osteonecrosis of the Jaw in Patients With Metastatic Renal Cell Carcinoma, Journal of Oral and Maxillofacial Surgery, vol.71, issue.9, pp.1532-1540, 2013.
DOI : 10.1016/j.joms.2013.03.019

J. Soria, F. Debraud, R. Bahleda, B. Adamo, F. Andre et al., Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors, Annals of Oncology, vol.25, issue.11, pp.2244-2251, 2014.
DOI : 10.1093/annonc/mdu390

J. Spano, C. Chodkiewicz, J. Maurel, R. Wong, H. Wasan et al., Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study, The Lancet, vol.371, issue.9630, pp.2101-2108, 2008.
DOI : 10.1016/S0140-6736(08)60661-3

J. Spano, M. J. Moore, Y. K. Pithavala, A. D. Ricart, S. Kim et al., Phase I study of axitinib (AG-013736) in combination with gemcitabine in patients with advanced pancreatic cancer, Investigational New Drugs, vol.12, issue.4, pp.1531-1539, 2012.
DOI : 10.1016/S1470-2045(11)70004-3

S. Stacchiotti, P. Collini, A. Messina, C. Morosi, M. Barisella et al., High-Grade Soft-Tissue Sarcomas: Tumor Response Assessment???Pilot Study to Assess the Correlation between Radiologic and Pathologic Response by Using RECIST and Choi Criteria, Radiology, vol.251, issue.2, pp.447-456, 2009.
DOI : 10.1148/radiol.2512081403

M. N. Stein and K. T. Flaherty, CCR Drug Updates: Sorafenib and Sunitinib in Renal Cell Carcinoma, Clinical Cancer Research, vol.13, issue.13, pp.3765-3770, 2007.
DOI : 10.1158/1078-0432.CCR-06-2844

D. Strumberg, A. Awada, H. Hirte, J. W. Clark, S. Seeber et al., Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?, European Journal of Cancer, vol.42, issue.4, pp.548-556, 1990.
DOI : 10.1016/j.ejca.2005.11.014

J. Tabernero, T. Yoshino, A. L. Cohn, R. Obermannova, G. Bodoky et al., Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study, RAISE Study Investigators, pp.499-508, 2015.
DOI : 10.1016/S1470-2045(15)70127-0

A. R. Tan, D. G. Gibbon, M. N. Stein, D. Lindquist, J. W. Edenfield et al., Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors, Cancer Chemotherapy and Pharmacology, vol.32, issue.suppl, pp.1635-1643, 2013.
DOI : 10.1111/j.1365-2036.2010.04469.x

M. J. Taphoorn, R. Henriksson, A. Bottomley, T. Cloughesy, W. Wick et al., Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma, Journal of Clinical Oncology, vol.33, issue.19, pp.2166-2175, 2015.
DOI : 10.1200/JCO.2014.60.3217

H. Thai, C. Veyrat-follet, F. Mentré, and E. Comets, Population pharmacokinetic analysis of free and bound aflibercept in patients with advanced solid tumors, Cancer Chemotherapy and Pharmacology, vol.104, issue.47, pp.167-180, 2013.
DOI : 10.1073/pnas.0708865104

URL : https://hal.archives-ouvertes.fr/inserm-00881821

P. S. Tofts, G. Brix, D. L. Buckley, J. L. Evelhoch, E. Henderson et al., Estimating kinetic parameters from dynamic contrast-enhanced t1-weighted MRI of a diffusable tracer: Standardized quantities and symbols, Journal of Magnetic Resonance Imaging, vol.10, issue.3, pp.223-232, 1999.
DOI : 10.1002/(SICI)1522-2586(199909)10:3<221::AID-JMRI1>3.0.CO;2-X

P. S. Tofts, Modeling tracer kinetics in dynamic Gd-DTPA MR imaging, Journal of Magnetic Resonance Imaging, vol.11, issue.1, pp.91-101, 1997.
DOI : 10.1006/jmrb.1993.1075

J. C. Uitdehaag, F. Verkaar, H. Alwan, J. De-man, R. C. Buijsman et al., A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug targets, British Journal of Pharmacology, vol.67, issue.3, pp.858-876, 2012.
DOI : 10.1158/0008-5472.CAN-06-4443

C. Urban and M. J. Anadkat, A review of cutaneous toxicities from targeted therapies in the treatment of colorectal cancers, J. Gastrointest. Oncol, vol.4, pp.319-327, 2013.

E. Van-cutsem, W. L. Vervenne, J. Bennouna, Y. Humblet, S. Gill et al., Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer, Journal of Clinical Oncology, vol.27, issue.13, pp.2231-2237, 2009.
DOI : 10.1200/JCO.2008.20.0238

E. Van-cutsem, J. Tabernero, R. Lakomy, H. Prenen, J. Prausová et al., Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen, Journal of Clinical Oncology, vol.30, issue.28, pp.3499-3506, 2012.
DOI : 10.1200/JCO.2012.42.8201

C. M. Van-kinschot, N. P. Van-erp, T. Feberwee, and V. O. Dezentjé, Sunitinib treatment in a patient with metastatic renal cell carcinoma and bariatric surgery, European Journal of Clinical Pharmacology, vol.9, issue.1, pp.1279-1281, 2015.
DOI : 10.1200/JCO.2005.02.2194

A. H. Varey, E. S. Rennel, Y. Qiu, H. S. Bevan, R. M. Perrin et al., VEGF165b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy, British Journal of Cancer, vol.50, issue.8, pp.1366-1379, 2008.
DOI : 10.1073/pnas.93.25.14765

A. A. Veldt, M. R. Van-der-meijerink, A. J. Eertwegh, J. B. Van-den-haanen, and E. Boven, Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib, British Journal of Cancer, vol.54, issue.5, pp.803-809, 2010.
DOI : 10.1038/sj.bjc.6605567

P. Vempati, A. S. Popel, and F. Mac-gabhann, Extracellular regulation of VEGF: Isoforms, proteolysis, and vascular patterning, Cytokine & Growth Factor Reviews, vol.25, issue.1, pp.1-19, 2014.
DOI : 10.1016/j.cytogfr.2013.11.002

R. B. Verheijen, S. Bins, R. H. Mathijssen, M. P. Lolkema, L. Van-doorn et al., Individualized Pazopanib Dosing: A Prospective Feasibility Study in Cancer Patients, Dutch Pharmacology Oncology Group, pp.5738-5746, 2016.
DOI : 10.1158/1078-0432.CCR-16-1255

G. Von-minckwitz, H. Eidtmann, M. Rezai, P. A. Fasching, H. Tesch et al., Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer, New England Journal of Medicine, vol.366, issue.4, pp.299-309, 1111065.
DOI : 10.1056/NEJMoa1111065

E. Vrdoljak, B. Rini, M. Schmidinger, T. Omr?en, L. Torday et al., Bisphosphonates and vascular endothelial growth factor-targeted drugs in the treatment of patients with renal cell carcinoma metastatic to bone, Anti-Cancer Drugs, vol.24, issue.5, pp.431-440, 2013.
DOI : 10.1097/CAD.0b013e328360335f

J. J. Vredenburgh, A. Desjardins, J. E. Herndon, J. Marcello, D. A. Reardon et al., Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme, Journal of Clinical Oncology, vol.25, issue.30, pp.4722-4729, 2007.
DOI : 10.1200/JCO.2007.12.2440

R. Wade, A. Duarte, M. Simmonds, R. Rodriguez-lopez, S. Duffy et al., The Clinical and Cost Effectiveness of Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy (FOLFIRI) for the Treatment of Metastatic Colorectal Cancer Which has Progressed Following Prior Oxaliplatin-Based Chemotherapy: a Critique of the Evidence, PharmacoEconomics, vol.30, issue.28, pp.457-466, 2015.
DOI : 10.1200/JCO.2012.42.8201

S. A. Wells, B. G. Robinson, R. F. Gagel, H. Dralle, J. A. Fagin et al., Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial, Journal of Clinical Oncology, vol.30, issue.2, pp.134-141, 2012.
DOI : 10.1200/JCO.2011.35.5040

P. Wolter, C. Stefan, B. Decallonne, H. Dumez, M. Bex et al., The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation, British Journal of Cancer, vol.24, issue.3, pp.448-454, 2008.
DOI : 10.1089/thy.2006.0308

Y. S. Wu, L. Shui, D. Shen, and X. Chen, Bevacizumab combined with chemotherapy for ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials, Oncotarget, vol.8, pp.10703-10713, 2017.
DOI : 10.18632/oncotarget.12926

C. F. Xu, Z. Xue, N. Bing, K. S. King, L. A. Mccann et al., Concomitant use of pazopanib and simvastatin increases the risk of transaminase elevations in patients with cancer, Annals of Oncology, vol.23, issue.9, pp.2470-2471, 2012.
DOI : 10.1093/annonc/mds249

H. Yu, N. Van-erp, S. Bins, R. H. Mathijssen, J. H. Schellens et al., Development of a Pharmacokinetic Model to Describe the Complex Pharmacokinetics of Pazopanib in Cancer Patients, Clinical Pharmacokinetics, vol.32, issue.5???6, pp.293-303, 2017.
DOI : 10.1007/s10928-005-0083-6

J. L. Zamorano, P. Lancellotti, D. Rodriguez-muñoz, V. Aboyans, R. Asteggiano et al., 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines, European Heart Journal, vol.37, issue.36, pp.2768-2801, 2016.
DOI : 10.1093/eurheartj/ehw211

X. Zhu, S. Wu, W. L. Dahut, and C. R. Parikh, Risks of Proteinuria and Hypertension With Bevacizumab, an Antibody Against Vascular Endothelial Growth Factor: Systematic Review and Meta-Analysis, American Journal of Kidney Diseases, vol.49, issue.2, pp.186-193, 2007.
DOI : 10.1053/j.ajkd.2006.11.039

X. Zhu, X. Tian, C. Yu, J. Hong, J. Fang et al., Increased risk of hemorrhage in metastatic colorectal cancer patients treated with bevacizumab, Medicine, vol.95, issue.34, 2016.
DOI : 10.1097/MD.0000000000004232